Physician profile
David L Kyle
NPI 1952370728
$5,937.64
in general payments reported to CMS, 2019-2025
35 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $34.41 · 2021: $659 · 2022: $1,020 · 2023: $1,151 · 2024: $1,395 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.63 | 2021-2025 | |
| Novo Nordisk INC | $643.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $592.44 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $575.73 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $485.15 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $295.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $288.35 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $210.82 | 2022-2025 | Ajovy, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.65 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $200.35 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $197.67 | 2021-2024 | Repatha, Otezla |
| Dexcom, INC. | $162.36 | 2021-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $148.29 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Glaxosmithkline, LLC. | $120.95 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Xeris Pharmaceuticals, INC. | $99.94 | 2023-2025 | Gvoke Hypopen |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.